JP2018065821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018065821A5 JP2018065821A5 JP2017218514A JP2017218514A JP2018065821A5 JP 2018065821 A5 JP2018065821 A5 JP 2018065821A5 JP 2017218514 A JP2017218514 A JP 2017218514A JP 2017218514 A JP2017218514 A JP 2017218514A JP 2018065821 A5 JP2018065821 A5 JP 2018065821A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- antigens
- cationic lipid
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161533512P | 2011-09-12 | 2011-09-12 | |
| US61/533,512 | 2011-09-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529976A Division JP6600459B2 (ja) | 2011-09-12 | 2012-09-12 | 粒子状ワクチン製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018065821A JP2018065821A (ja) | 2018-04-26 |
| JP2018065821A5 true JP2018065821A5 (enExample) | 2018-06-28 |
Family
ID=47883670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529976A Active JP6600459B2 (ja) | 2011-09-12 | 2012-09-12 | 粒子状ワクチン製剤 |
| JP2017218514A Pending JP2018065821A (ja) | 2011-09-12 | 2017-11-13 | 粒子状ワクチン製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529976A Active JP6600459B2 (ja) | 2011-09-12 | 2012-09-12 | 粒子状ワクチン製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20150110823A1 (enExample) |
| EP (1) | EP2755680B1 (enExample) |
| JP (2) | JP6600459B2 (enExample) |
| CN (2) | CN104066444A (enExample) |
| ES (1) | ES2689799T3 (enExample) |
| PL (1) | PL2755680T3 (enExample) |
| TW (1) | TWI673062B (enExample) |
| WO (1) | WO2013039989A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| AU2009236306B2 (en) | 2008-04-17 | 2015-04-02 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| WO2013039989A1 (en) * | 2011-09-12 | 2013-03-21 | Pds Biotechnology Corporation | Particluate vaccine formulations |
| US10286064B2 (en) | 2012-06-15 | 2019-05-14 | Pds Biotechnology Corporation | Cationic lipid vaccine compositions and methods of use |
| AU2013317805B2 (en) | 2012-09-21 | 2018-07-26 | Pds Biotechnology Corporation | Improved vaccine compositions and methods of use |
| US11612652B2 (en) | 2015-11-13 | 2023-03-28 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
| WO2018067822A1 (en) * | 2016-10-05 | 2018-04-12 | Pds Biotechnology Corporation | Methods to alter the tumor microenvironment for effective cancer immunotherapy |
| CN119033925A (zh) * | 2016-10-05 | 2024-11-29 | Pds生物科技公司 | 新型hpv16非hla限制性t细胞疫苗、组合物及其使用方法 |
| TW201924722A (zh) | 2017-12-05 | 2019-07-01 | 美商Ｐｄｓ生技公司 | 用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物 |
| AU2020207087A1 (en) * | 2019-01-12 | 2021-08-12 | The Methodist Hospital | Self-assembled peptide nanoparticle and use thereof |
| WO2021085696A1 (ko) * | 2019-11-01 | 2021-05-06 | 한국과학기술원 | 작은 지질 나노 입자 및 이를 포함하는 암 백신 |
| WO2023145749A1 (ja) * | 2022-01-27 | 2023-08-03 | 一般財団法人阪大微生物病研究会 | 免疫賦活剤 |
| WO2023203214A1 (en) | 2022-04-22 | 2023-10-26 | Universitat Autònoma De Barcelona | Immunogenic composition with protein micro- and nanoparticles |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6183745B1 (en) * | 1990-12-12 | 2001-02-06 | The University Of Queensland | Subunit papilloma virus vaccine and peptides for use therein |
| AUPM500494A0 (en) * | 1994-04-12 | 1994-05-05 | Minister For Agriculture & Rural Affairs For The State Of New South Wales, The | Composition for use in increasing mucosal immunity |
| JPH11510046A (ja) * | 1995-07-21 | 1999-09-07 | ローヌ−プーラン ローラー ファーマシューティカルズ インコーポレイテッド | アデノ関連ウイルスリポソーム及び樹状細胞をトランスフェクトして特異性免疫を刺激することにおけるそれらの使用 |
| FR2794370B1 (fr) | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
| WO2002060412A2 (en) * | 2001-02-01 | 2002-08-08 | Board Of Regents | Stabilised polymeric aerosols for pulmonary gene delivery |
| US20050031587A1 (en) * | 2002-10-04 | 2005-02-10 | Yamanouchi Pharmaceutical Co., Ltd. | Immune response induction method |
| WO2005037190A2 (en) * | 2003-09-03 | 2005-04-28 | Dendritherapeutics, Inc. | Multiplex vaccines |
| CN1559607A (zh) * | 2004-02-20 | 2005-01-05 | �й�ũҵ��ѧ | 一种核酸物质与蛋白质类组合物及其生产方法和在免疫调节中的应用 |
| US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
| DE102004057303A1 (de) * | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
| WO2007022152A2 (en) * | 2005-08-15 | 2007-02-22 | The Research Foundation Of State University Of New York | Lipid nano particulates containing antigens as cancer vaccines |
| WO2007081447A2 (en) * | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| JP2007238559A (ja) * | 2006-03-10 | 2007-09-20 | Nagoya City Univ | 未成熟樹状細胞活性化剤及びその使用 |
| US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| AU2009236306B2 (en) * | 2008-04-17 | 2015-04-02 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| WO2011109294A1 (en) * | 2010-03-01 | 2011-09-09 | Dicerna Pharmaceuticals, Inc. | Lipid delivery formulations |
| WO2013039989A1 (en) * | 2011-09-12 | 2013-03-21 | Pds Biotechnology Corporation | Particluate vaccine formulations |
-
2012
- 2012-09-12 WO PCT/US2012/054786 patent/WO2013039989A1/en not_active Ceased
- 2012-09-12 CN CN201280055234.5A patent/CN104066444A/zh active Pending
- 2012-09-12 JP JP2014529976A patent/JP6600459B2/ja active Active
- 2012-09-12 EP EP12831495.2A patent/EP2755680B1/en active Active
- 2012-09-12 PL PL12831495T patent/PL2755680T3/pl unknown
- 2012-09-12 ES ES12831495.2T patent/ES2689799T3/es active Active
- 2012-09-12 US US14/344,327 patent/US20150110823A1/en not_active Abandoned
- 2012-09-12 CN CN201910145079.XA patent/CN110075292A/zh active Pending
- 2012-09-12 TW TW101133392A patent/TWI673062B/zh not_active IP Right Cessation
-
2017
- 2017-11-13 JP JP2017218514A patent/JP2018065821A/ja active Pending
-
2019
- 2019-03-21 US US16/360,278 patent/US20190275145A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hess et al. | Phage display as a tool for vaccine and immunotherapy development | |
| Marasini et al. | Oral delivery of nanoparticle-based vaccines | |
| Ninomiya et al. | Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice | |
| Kallerup et al. | Classification of vaccines | |
| JP5331340B2 (ja) | インフルエンザウィルスワクチン組成物、及びその使用方法 | |
| JP2014522842A5 (enExample) | ||
| JP2014520807A5 (enExample) | ||
| Naskalska et al. | Virus like particles as immunogens and universal nanocarriers | |
| Li et al. | Bacteriophage T4 vaccine platform for next-generation influenza vaccine development | |
| JP2018534304A5 (enExample) | ||
| JP2017035093A5 (enExample) | ||
| TWI673062B (zh) | 粒狀疫苗調配物 | |
| JP2017507117A5 (enExample) | ||
| EP4091630A1 (en) | Vaccines comprising r-dotap | |
| Donaldson et al. | Virus-like particles, a versatile subunit vaccine platform | |
| JP2016185988A5 (enExample) | ||
| JP2011504486A5 (enExample) | ||
| Even-Or et al. | Adjuvanted influenza vaccines | |
| Kianmehr et al. | Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice | |
| JP2015504897A5 (enExample) | ||
| Patel et al. | Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses | |
| Hendy et al. | Nano/microparticle Formulations for Universal Influenza Vaccines: Nano/microparticle Formulations for Universal Influenza Vaccines | |
| de Moura et al. | Enhancing the effect of nucleic acid vaccines in the treatment of HPV-related cancers: an overview of delivery systems | |
| JP2021521149A5 (enExample) | ||
| Feng et al. | RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2 |